DAWEX
22.4.2024 08:31:26 CEST | Business Wire | Press release
Data4Industry-X, the trusted data exchange solution for Industry, carries on its dynamics to bring the most comprehensive and flexible solution on the market for industrial organizations aiming at boosting competitiveness and minimizing carbon footprint. Recognized as a Gaia-X Lighthouse project and contributing to the Manufacturing-X initiative, the Data4Industry-X solution is designed to accelerate data & information exchange between global organizations, subsidiaries and suppliers by leveraging the most advanced, secure and compliant data exchange technology on the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240421440918/en/
Supported by the AIF (Alliance pour l’industrie du futur), and initially responding to the power generation and automotive markets, Data4Industry-X gathers technological & industrial expertise from Dawex, Schneider Electric, Valeo, CEA, and Prosyst, in order to deliver broad cross-border, cross-company, cross-factory industrial data exchanges.
Industrial organizations with plants, shop floors and suppliers, spread across the globe with decentralized manufacturing, are concerned by their ability to bring innovations and operational efficiencies to increase competitiveness, while reducing CO2 emissions to meet and report on their sustainability obligations.
With the objective to support the digital transformation of all industry stakeholders and create a compelling industry data ecosystem encompassing all sizes of organizations, Data4Industry-X solution relies on Dawex Data Exchange technology. The solution is based on open and cloud-agnostic architecture, to deliver a trusted, secure, sovereign and compliant data exchange environment that implements the Gaia-X de facto standards. Powered by this technology, the Data4Industry-X solution will use the Eclipse Dataspace Component framework to facilitate interoperability between data spaces. Additionally, thanks to the UDC (Unified Data Collector) Prosyst solution, Data4Industry-X interfaces with OPC UA protocol to retrieve industrial data and exchange them at scale with the broad ecosystem.
By relying on technological and industrial expertise, Data4Industry-X becomes the most agnostic, flexible and advanced data exchange solution for Industry, designed in compliance with the new European data regulations, such as the Data Act and the Data Governance Act, capable of operating in any industrial situation, with all types of companies.
The Data4Industry-X solution will bridge the entire industry data ecosystem by enabling large and small organizations in all sectors to exchange, distribute and valorize industrial data, securely, to ultimately improve operational efficiency and meet decarbonation objectives.
“Data4Industry-X pursues its dynamics to deploy the most advanced data exchange solution for the industry to accelerate innovation, better control carbon footprint, and gain competitive advantage thanks to data circulation.” said Laurent Lafaye, co-CEO at Dawex. “Data4Industry-X will ultimately empower all industry stakeholders, of all sizes, to engage into data exchange and contribute to fostering a resilient and sustainable industry ecosystem by benefiting from the full potential of data”.
Data4Industry-X is supported by the French government’s France 2030 initiative and the European program Next Generation.
About Dawex
About Schneider Electric
About Valeo
About CEA-List
About Prosyst
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240421440918/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom